Etanercept in severe, recalcitrant psoriasis: Clinical response, safety profile and predictors of response based on a single institution's experience

Journal of the European Academy of Dermatology and Venereology

Volumn 23, Issue 8, 2009, Pages 979-982

  Antoniou, C ^a   Dessinioti, C ^a   Stratigos, A ^a   Avgerinou, G ^a   Stavropoulos, P ^a   Katsambas, A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE;

ADULT; AGED; BALANITIS; BRAIN HEMANGIOMA; BREAST CANCER; BRONCHITIS; COMORBIDITY; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HERPES SIMPLEX; HUMAN; INJECTION SITE REACTION; LETTER; LIPID DISORDER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PSORIASIS; PUVA; RISK BENEFIT ANALYSIS; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; WALKING INSTABILITY; WEIGHT GAIN;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67651171594     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2009.03093.x     Document Type: Letter

References (10)

1. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003 349 : 2014 2022.
2. Haitz KA, Kalb RE. Infliximab for the treatment of psoriasis in patients previously treated with etanercept. J Am Acad Dermatol 2007 57 : 120 125.
3. Sfikakis PP, Iliopoulos A, Elezoglou A et al. Psoriasis induced by anti-tumour necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005 52 : 2513 2518.
4. Paul CF, Ho VC, McGeown C et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. Invest Dermatol 2003 120 : 211 216.
5. Antoniou C, Dessinioti C, Katsambas A, Stratigos AJ. Elevated triglyceride and cholesterol levels after intravenous antitumour necrosis-α therapy in a patient with psoriatic arthritis and psoriasis vulgaris. Br J Dermatol 2007 156 : 1090 1091.
6. De Groot M, Appelman M, Spuls PI, de Rie MA, Bos JD. Initial experience with routine administration of etanercept in psoriasis. Br J Dermatol 2006 155 : 808 814.
7. Strober B, Gottlieb A, Leonardi C et al. Levels of response of psoriasis patients with different baseline characteristics treated with etanercept. Poster P2890 presented at: Annual meeting of the American Academy of Dermatology March 4, 2006 : San Francisco, CA.
8. Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol 2008 58 : 443 446.
9. Elkayam O, Ophir J, Yaron M, Caspi D. Psoriatic arthritis: interrelationships between skin and joint manifestations related to onset, course, and differentiation. Clin Rheum 2000 19 : 301 305.
10. Ciocon DH, Kimball AB. Psoriasis and psoriatic arthritis. separate or one and the same? Br J Dermatol 2007 157 : 850 860.